drugset / Trial / NCT02251119

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

NCT02251119

Phase 1 Completed 24 enrolled Boehringer Ingelheim
Parallel-groupOpen-labelTreatment

Summary

The objective of the study was to determine if the co-administration of loperamide (LOP) with tipranavir (TPV), ritonavir (RTV), or TPV plus RTV (TPV/r) caused a clinically significant change in the respiratory response to carbon dioxide (CO2), defined as a 10% decrease in the area under the pharmacodynamic effect/time curve or at least a 25% decrease in at least one pharmacodynamic time point.

Timeline

Start
2002-07
Primary completion
2003-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Loperamide Small molecule
Subject Ritonavir Other / unclassified
Subject Tipranavir Small molecule

Indications

No indication recorded.